Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.

Thea Anine Strøm HaldenKine Eide KvitneKarsten MidtvedtLaavanyaah RajakumarIda RobertsenJan BroxJens BollerslevAnders HartmannAnders ÅsbergTrond Jenssen

Published in: Diabetes care (2019)

Empagliflozin appeared safe and improved glycemic control in renal transplant recipients with PTDM compared with placebo. A concomitant reduction in body weight was seen.

Keyphrases

glycemic control
body weight
type diabetes
blood glucose
weight loss
insulin resistance
clinical trial
metabolic syndrome
skeletal muscle
study protocol